Drugs of abuse share the ability to enhance dopaminergic neurotransmission in the dorsal and ventral striatum. The action of dopamine is modulated by additional neurotransmitters, including glutamate, serotonin and adenosine. All these neurotransmitters regulate the phosphorylation state of Dopaminal serine/threonine protein phosphatase, PP-1. Phosphorylatine-and cAMP-regulated phosphoprotein, Mr 32 kDa . Phosphorylation at Thr 34 by protein kinase A converts DARPP-32 into a potent inhibitor of the multifunctioon at Thr 75 by Cdk5 converts DARPP-32 into an inhibitor of protein kinase A. The state of phosphorylation of DARPP-32 at Thr 34 also depends on the phosphorylation state of Ser 97 and Ser 130 , which are phosphorylated by CK2 and CK1, respectively. By virtue of regulation of these 4 phosphorylation sites, and through its ability to modulate the activity of PP-1 and protein kinase A, DARPP-32 plays a key role in integrating a variety of biochemical, electrophysiological, and behavioral responses controlled by dopamine and other neurotransmitters. Importantly, there is now a large body of evidence that supports a key role for DARPP-32-dependent signaling in mediating the actions of multiple drugs of abuse including cocaine, amphetamine, nicotine, caffeine, LSD, PCP, ethanol and morphine.
DARPP-32, A MULTIFUNCTIONAL REGULATOR OF PROTEIN KINASES AND PROTEIN PHOSPHATASES
Dopamine-and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32), was initially discovered as a major target for dopamine-activated adenylyl cyclase and protein kinase A (PKA) in striatum. 1 Phosphorylation by PKA at Thr 34 converts DARPP-32 into a potent high-affi nity inhibitor of the multifunctional serine/threonine protein phosphatase, PP-1. The IC 50 for inhibition of PP-1 is ~10 − 9 M. 2 Since DARPP-32 is expressed in very high concentration (~50 m M) in all medium spiny neurons, 3 including those in both the striatonigral and striato pallidal projection pathways (see below), and the concentration of all PP-1 isoforms is likely less than 20 m M, 4 a substantial proportion of PP-1 activity will be inhibited in response to even moderate increases in DARPP-32 phosphorylation.
Detailed structure-function studies have established that the fi rst 40 amino acids at the NH 2 -terminus of DARPP-32 are suffi cient (when Thr 34 is phosphorylated) for DARPP-32 to bind to and inhibit PP-1. Moreover, several different types of biochemical approaches have revealed that the remaining COOH-terminal portion of DARPP-32 serves an important role in the modulation of DARPP-32 function. In intact neurons, DARPP-32 is highly phosphorylated at Ser 97 and Ser 130 under basal conditions. Ser 97 is phosphorylated by CK2 and Ser 130 is phosphorylated by CK1. In vitro, phosphorylation of Ser 97 of DARPP-32 increases the effi ciency of phosphorylation of Thr 34 by PKA. 5 In vitro, phosphorylation of Ser 130 decreases the rate of dephosphorylation of Thr 34 by PP-2B, 6 and in striatal slices, DARPP-32 phosphorylated at Ser 130 is phosphorylated to a higher level at Thr 34 . 7 The overall consequence of phosphorylation of DARPP-32 by CK1 or CK2 in intact cells is to increase the state of phosphorylation of Thr 34 . The physiological role of these two phosphorylation events is to potentiate D1 dopaminergic signaling through the DARPP-32/PP-1 pathway.
A variety of recent studies have found that DARPP-32 is a physiological target for the proline-directed kinase, cdk5/p35, a cyclin-dependent kinase family member that is highly expressed in post-mitotic neurons where it is activated by the non-cyclin cofactor p35. 8 In vitro, phosphorylation of DARPP-32 at Thr 75 does not alter the kinetics of phosphorylation by either CK1 or CK2. However, phosphorylation of Thr 75 has a major inhibitory effect on the phosphorylation of Thr 34 by PKA, and has a general inhibitory effect on phosphorylation of other PKA substrates. The resultant decrease in phosphorylation of Thr 34 of DARPP-32 would act to inhibit D 1 dopamine signaling through the DARPP-32/PP-1 cascade. levels of DARPP-32 are found in the striatum (caudateputamen and nucleus accumbens), olfactory tubercle, bed nucleus of stria terminalis, and portions of the amygdaloid complex. These brain regions send projections to various target areas, including globus pallidus, ventral pallidum, the entopeduncular nucleus, and substantia nigra pars reticulata. Although concentrated in the striatum, it is important to note that moderate levels of DARPP-32 are found throughout the neocortex, with particular enrichment in layers II, III, and VI, in the dentate gyrus of the hippocampus and in the choroid plexus. There are also low levels of DARPP-32 in several other brain regions including hypothalamus and cerebellum. Within the striatum, DARPP-32 is found in medium-sized spiny neurons. Medium spiny neurons constitute the major cell type (95%) in the striatum, are inhib itory, and utilize GABA as their major neurotransmitter. 10 At the ultrastructural level, DARPP-32 has been found in most cytosolic subcellular compartments of medium spiny neurons, including dendrites, axons and axon terminals. Some nuclei also appear to contain DARPP-32 immunoreactivity.
Medium spiny neurons can be divided into two equally large subpopulations based on their peptide content and their projection areas. [11] [12] [13] One subpopulation contains substance P and dynorphin and projects directly to substantia nigra pars reticulata and the entopeduncular nucleus (the direct striatonigral pathway). The other subpopulation contains enkephalin and projects indirectly to these structures via relays in the globus pallidus and subthalamic nucleus (the indirect striatopallidal pathway). DARPP-32 is expressed at high levels in both striatonigral and striatopal lidal neurons. Large-sized cholinergic interneurons and mediumsized GABAergic interneurons are devoid of DARPP-32 immunoreactivity. 14 , 15 
REGULATION OF THE PHOSPHORYLATION OF DARPP-32 BY DOPAMINE, GLUTAMATE, SEROTONIN AND ADENOSINE
Within medium spiny neurons, a major role for dopamine is to modulate the actions of glutamate. Cross-talk between dopamine and glutamate plays important roles in the regulation of emotion, mood, reward, and cognition. Pertubations of these neurotransmitter systems are thought to contribute to the etiology of several common neuropsychiatric disorders, including schizophrenia, bipolar disorder and ADHD, and to play an important role in the actions of drugs of abuse. In addition to dopamine and glutamate, serotonin is also highly involved in the regulation of mood and reward and in the actions of several drugs of abuse. Indeed, the psychostimulants cocaine and amphetamine act on both dopamine and serotonin reuptake transporters and cause signifi cant increases in the extracellular levels of these two monoamines in various regions of the brain, particularly in the striatum and nucleus accumbens. 16 , 17 We shall briefl y review some of the studies of regulation of DARPP-32 by dopamine, glutamate and serotonin. As adenosine A 2A receptors are critical for the actions of caffeine and are important in the regulation of DARPP-32 phosphorylation in striatopallidal neurons, we will also briefl y review the regulation of DARPP-32 by adenosine. For a more detailed discussion of these and other neurotransmitters, neuromodulators and neuropeptides see. 22 However, biochemical and physiological evidence supports the idea that there is also a population of medium spiny neurons that express both D 1 and D 2 types of receptor. 23 , 24 As a consequence of the actions of the different types of receptors, dopamine regulates the state of phosphorylation of DARPP-32 in a bidirectional manner. In striatal slices or whole animals, activation of D 1 receptors, via stimulation of PKA, results in phosphorylation of DARPP-32 at Thr 34 . 21 , 25 This effect is counteracted by the activation of D 2 receptors via inhibition of adenylyl cyclase and via stimulation of Ca 2+ -dependent activation of calcineurin. 21 ; 26 Activation of D 1 receptors also decreases the phosphorylation state of DARPP-32 at Thr 75 by a process that appears to involve the PKA-dependent activation of PP-2A. 27 Thus, enhanced dopaminergic transmission via D 1 receptors leads to a decreased phosphorylation of Thr 75 -DARPP-32, which reduces inhibition of PKA and thereby facilitates signaling via the PKA/Thr 34 -DARPP-32/PP-1 cascade.
Glutamate:
The regulation of DARPP-32 phosphorylation by glutamate is complex and involves the actions of both ionotropic (NMDA and AMPA) and metabotropic (mGlu) glutamate receptors. Glutamate, released at glutamatergic nerve terminals, activates NMDA-and AMPA-type receptors, leading to a decrease in DARPP-32 Thr 34 E355 phosphorylation through the Ca 2+ -dependent activation of calcineurin. 28 , 29 Activation of NMDA and AMPA receptors also results in a decrease in Thr 75 phosphorylation. 29 Surprisingly, the regulation of Thr 75 phosphorylation is not mediated through Ca 2+ -dependent activation of calcineurin, but rather via Ca 2+ -dependent activation of PP-2A, and involves a mechanism that is not yet fully understood. The primary action of glutamate through NMDA and AMPA receptors is to reduce phosphorylation of Thr 34 and as a result to activate PP-1. However, under conditions where Thr 34 phosphorylation is low, the dephosphorylation of Thr 75 and the resulting disinhibition of PKA caused by glutamate may act to potentiate dopamine/D 1 receptor/PKA/ phospho-Thr 34 DARPP-32 signaling.
Metabotropic glutamate receptors are subdivided into three groups: group I (mGlu1 and mGlu5 receptors), group II (mGlu2 and mGlu3 receptors), and group III (mGlu4, mGlu6, mGlu7, and mGlu8 receptors). 30 Group I mGlu receptors are expressed in both direct and indirect pathway neostriatal neurons, 31 and group II and III mGlu receptors are expressed on the terminals of corticostriatal afferents. 32 Activation of mGlu5 receptors in striatal slices stimulates DARPP-32 Thr 34 phosphorylation, an effect that is dependent on activation of adenosine A 2A receptors by endogenous adenosine. 33 This study has further suggested that there is a synergistic interaction of mGlu5 receptors and adenosine A 2A receptors at the level of production of cAMP, and that this effect of mGlu5 receptors requires MAP kinase signaling.
Group I mGlu receptors also regulate the phosphorylation of DARPP-32 at Thr 75 and Ser 130 . Treatment of striatal slices with a group I mGlu receptor agonist stimulates the activity of CK1, leading to an increase in the phosphorylation of DARPP-32 at Thr 75 and Ser 130 . 34 , 35 Detailed analysis of the mechanism of CK1 activation revealed that group I mGlu receptors, coupled to G q , activate phospholipase C and stimulate the generation of inositol triphosphate, leading to an increase in intracellular Ca 2+ . The increased intracellular Ca 2+ activates calcineurin, causing dephosphorylation of inhibitory autophosphorylation sites in CK1. Activation of CK1 causes phosphorylation of Ser 130 and results in activation of Cdk5 and phosphorylation of Thr 75 by an unknown mechanism.
The relative temporal contributions of ionotropic and metabotropic glutamate receptors in mediating effects of glutamate on phosphorylation of DARPP-32 at Thr 34 and Thr 75 have been recently studied. 36 Treatment with glutamate caused a complex change in DARPP-32 Thr 34 phosphorylation. An initial rapid increase in Thr 34 phosphorylation was NMDA/AMPA/mGlu5 receptor-dependent and was mediated through activation of a neuronal nitric oxide synthase/nitric oxide/cGMP/cGMP-dependent kinase signaling cascade. A subsequent decrease in phosphorylation was attributable to activation of an NMDA/AMPA receptor/Ca 2+ /calcineurin signaling cascade. This decrease was followed by rephosphorylation via a pathway involving a mGlu5 receptor/phospholipase C and MAP kinase signaling cascade. Treatment with glutamate initially decreased Thr 75 phosphorylation through activation of NMDA/AMPA receptor/Ca 2+ /PP-2A signaling. Thereafter, glutamate slowly increased Thr 75 phosphorylation through activation of mGlu1 receptor/phospholipase C signaling.
Serotonin: Various serotonin receptors, including 5-HT 1B , 5-HT 1F , 5-HT 2A , 5-HT 2C , 5-HT 3 , 5-HT 4 , and 5-HT 6 , are expressed in medium spiny neurons in the striatum. 37 These receptors act primarily via the following second messenger systems: 5-HT 1B/E receptors decrease cAMP formation, 5-HT 2A/C receptors increase inositol triphosphate and diacylglycerol production, 5-HT 3 receptors increase Na + and Ca 2+ infl ux, and 5-HT 4 and 5-HT 6 receptors increase cAMP formation. Studies in striatal slices and whole animals have shown that serotonin stimulates phosphorylation of DARPP-32 at Thr 34 and decreases phosphorylation at Thr 75 primarily via activation of 5-HT 4 and 5-HT 6 receptors. 38 Serotonin stimulates phosphorylation of Ser 130 -DARPP-32 primarily via 5-HT 2 receptors. As a consequence of their actions on DARPP-32 phosphorylation, these three serotonin pathways act synergistically to inhibit PP-1.
Adenosine : Adenosine is found intra-and extracellularly in all organs of the body. Most adenosine is formed via breakdown of ATP intracellularly and transported to the extracellular space via equilibrative transporters. Extracellular adenosine acts via G-protein-coupled receptors of which two, A 1 and A 2A receptors, are abundantly expressed in the brain. Adenosine A 1 receptors inhibit, and A 2A receptors stimulate, adenylyl cyclase. A 1 receptors have a widespread distribution in the brain, with the highest levels in hippocampus and cerebellum, whereas A 2A receptors are almost exclusively found in striatum where they are restricted to striatopallidal neurons. 39 In striatal slices, the A 2A receptor agonist CGS21680 was found to increase the level of DARPP-32 phosphorylated at Thr 34 in a concentrationdependent manner. 40 When treatment with CGS 21680 was combined with treatment with SKF81297, a selective D 1 agonist, an additive response was observed both on cAMP levels and Thr 34 -DARPP-32 phosphorylation. In whole animals, in vivo, antagonists at A 2A and D 1 receptors had an additive effect in reducing DARPP-32 phosphorylation. 25 
ROLE OF DARPP-32 PHOSPHORYLATION IN THE ACTIONS OF DRUGS OF ABUSE
It is well established that the dopaminergic system plays an important role in reward-related behaviors, and drugs with reinforcing properties share the ability to increase dopaminergic transmission. 42 , 43 By virtue of its regulation by dopamine, as well as by other neurotransmitters linked to the actions of drugs of abuse, DARPP-32 is positioned to play an important role in either mediating or modulating the short, and perhaps long, term actions of drugs of abuse. The generation of DARPP-32 knockout (KO) mice, 44 and the more recent generation of mice in which individual phosphorylation sites have been mutated, 45 have provided powerful animal models for use in studies of the role of DARPP-32 in the actions of drugs of abuse. A wide variety of approaches using these mouse models have demonstrated that DARPP-32 mediates many biochemical, electrophysiological, gene transcriptional, and behavioral effects of dopamine. A general feature of the results obtained is that DARPP-32 is required for the actions of physiological concentrations of dopamine, while the consequences of the lack of DARPP-32 are less pronounced at higher, supraphysiological, concentrations of dopamine. We will briefl y summarize these recent studies of DARPP-32 mutant mice as well as summarize studies of the regulation of DARPP-32 phosphorylation by a variety of drugs of abuse. 18 , 46 , 47 Cocaine and amphetamine: Cocaine inhibits reuptake of dopamine, whereas amphetamine promotes release of dopamine from nerve terminals through a weak-basemediated reverse transport mechanism. 42 48 has demonstrated that the psychostimulant-induced phosphorylation of Thr 34 -DARPP-32 occurs primarily in striatonigral neurons. Chronic treatment with cocaine upregulates the expression of both Cdk5 and p35 in striatum, and this leads to increased phosphorylation of Thr 75 of DARPP-32 and consequently to decreased phosphorylation of Thr 34 . 49 A well-known behavioral effect of repeated cocaine administration is the development of sensitization. Notably, intraaccumbal application of Cdk5 inhibitors was found to potentiate cocaine-induced behavioral sensitization, 49 indicating that Cdk5 is likely to be involved in counteracting this sensitization phenomenon.
From studies of DARPP-32 KO and phospho-site knockin mice, DARPP-32 is likely to be involved in changes in gene transcription that are important for maintaining altered synaptic function and for initiating adaptive morphological changes of the type believed to underlie the effects of various drugs of abuse. Treatment of animals with cocaine increases the phosphorylation state of CREB, ELK, and multiple immediate early genes. 42 , 43 CREB, c-Fos, Fras, and many other immediate early genes regulate gene transcription and may coordinate alterations in gene expression, leading to long-term changes in neuronal function. Dopamine, via activation of D 1 receptors and PKA, stimulates phosphorylation of CREB at Ser 133 in striatum, 50 and the dephosphorylation of CREB at Ser 133 is under the control of PP-1. 51 Other transcription factors, such as ELK, are regulated by the MAP kinase signaling cascade. 42 Notably, dopamine receptor-mediated activation of MAP kinase, CREB, c-Fos, and D FosB is strongly attenuated in DARPP-32 KO mice. 13 , 52 , 53 A detailed study of the regulation of the MAP kinase signaling cascade by DARPP-32 showed a prominent role of Thr 34 -DARPP-32/PP-1 signaling. 48 Inhibition of PP-1 appears to be important at several levels for activating the ERK cascade. On the one hand, it prevents extracellular regulated kinase (ERK) dephosphorylation by striatal enriched phosphatase (STEP), by maintaining this tyrosine phosphatase in a phosphorylated, inactive, state. On the other hand, PP-1 is also critical upstream of ERK, because MEK phosphorylation in response to psychostimulants was dramatically reduced in DARPP-32 KO mice.
Several alterations in the behavioral responses to acute and chronic treatment with cocaine are exhibited in DARPP-32 KO mice. An attenuated locomotor responsiveness to a single injection of cocaine is found in DARPP-32 KO mice compared with wild-type mice. 44 In contrast, following chronic treatment with cocaine, DARPP-32 KO mice show increased locomotor sensitization as compared with wildtype mice. 54 The different involvement of DARPP-32 in acute and chronic responses to cocaine may be related to the differences in the relative levels of Thr 75 -DARPP-32 and Thr 34 -DARPP-32, which have been found following acute vs chronic treatment with cocaine, and the antagonistic relationship between these two sites. 27 , 49 The acquisition of place-preference is also signifi cantly attenuated in DARPP-32 KO mice. 55 , 56 The effects of D-amphetamine on two other behavioral parameters -sensorimotor gating and repetitive movements -were also greatly diminished in DARPP-32 KO, Thr 34 Ala-DARPP-32 and Ser 130 Ala-DARPP-32 mice. 45 Opioids: Opiates regulate striatal function via an indirect action on mesencephalic dopamine neurons and a direct action on opioid receptors located within striatum. 43 There is a relatively abundant expression of all three opioid receptor sub-types ( m , d , and k ) in striatum. 57 , 58 k opioid receptors are expressed primarily on dopaminergic nerve terminals, whereas m -and d -receptors are expressed in medium spiny neurons. m -receptors appear to be enriched in striatonigral neurons where they are colocalized with D 1 receptors. d -receptors are highly expressed in cholinergic interneurons, but there is also some expression in striatopallidal neurons. Both m -and d -receptors are negatively coupled to adenylyl cyclase. In striatal slices, activation of opioid receptors was found to modulate the effects of dopamine and adenosine on DARPP-32 phosphorylation at Thr 34 . 59 Nicotine: Nicotine has been shown to modulate dopaminergic neurotransmission mainly by enhancing dopamine release in nigrostriatal and mesolimbic dopaminergic systems. 60 , 61 Five types of a subunits ( a 2-a 6) and three types of b subunits ( b 2-b 4) constitute a and b type heteromeric nicotinic acetylcholine receptors (nAChRs), whereas a 7 subunits constitute homomeric nAChRs. 62 Four major populations of nAChRs are expressed at dopaminergic terminals in the striatum, with the major subtype containing a 4 b 2 subunits. 63 The other predominant subtype, a 7, is expressed at glutamatergic terminals in the striatum. 64 Acute application of nicotine in mouse neostriatal slices produces a dose-dependent response, with a low concentration (1 m M) causing a sustained decrease in DARPP-32 Thr 34 phosphorylation, and a high concentration (100 m M) causing a transient increase in Thr 34 phosphorylation. 65 Using a variety of pharmacological reagents, nicotine at a low concentration (1 m M) has been found to stimulate a 4 b 2-containing nAChRs at dopaminergic terminals. Activation of a 4 b 2 nAChRs results in the release of dopamine, and the released dopamine selectively activates dopamine D 2 receptor signaling, leading to a reduction in phosphorylation at Thr 34 . Conversely, nicotine at a high concentration (100 m M) was found to stimulate both a 4 b 2 nAChRs at dopaminergic terminals and a 7 nAChRs at glutamatergic terminals. Activation of a 7 nAChRs results in the release of glutamate. Co-activation of a 4 b 2 nAChRs by nicotine, and of NMDA/AMPA receptors by glutamate, synergistically induces robust dopamine release, leading to the activation of dopamine D 1 receptors and phosphorylation of Thr 34 . Thus, depending on the amount of dopamine released locally in response to low and high concentrations of nicotine, either dopamine D 2 receptor signaling in striatopallidal neurons or dopamine D 1 receptor signaling in striatonigral neurons is predominantly activated. Lysergic acid diethylamide (LSD) and Phencyclidine (PCP): LSD and other related hallucinogens act via multiple serotonin receptors, including 5-HT 2 , 5-HT 5 and 5-HT 6 receptors. 66 , 67 Behavioral studies using discrimination paradigms have suggested a major role for 5-HT 2 receptors in mediating the discriminative stimulus effects of hallucinogens. 68 Stimulation of 5-HT2 receptors increases Ser 130 -DARPP-32 in slices and LSD also signifi cantly increases phosphorylation of Ser 130 -DARPP-32 in mice. 45 LSD had similar effects on Ser 130 -DARPP-32 in slices prepared from striatum and in striata from whole animals. LSD also increased phosphorylation at Thr 34 -DARPP-32. In slices, but not in striata from whole animals, LSD decreased Thr 75 -DARPP-32. PCP acts as a non-competitive antagonist at NMDA receptors and causes a complex behavioral response. In general, NMDA receptor antagonists can produce psychotic symptoms in humans that are indistinguishable from acute episodes of schizophrenia. As a result, glutamatergic dysfunction has been proposed as an underlying cause of the pathophysiology of schizophrenia. 69 Hence, NMDA receptor antagonists, such as PCP, have been used extensively to pharmacologically model psychosis in animals. However, PCP also potently regulates the reward system. Rats can be trained to self-administer PCP. 70 Interestingly, this effect appears to be largely dopamine-independent. Furthermore, PCP-induced locomotor stimulation and potentiation of cocaine reinforcement, can occur without a concomitant increase in dopamine release. 71 , 72 PCP as well as MK801, another NMDA antagonist, increases Thr 34 -DARPP-32 phosphorylation. 21 , 45 PCP also increases Ser 130 -DARPP-32, but has no effect on Thr 75 -DARPP-32. 45 The pattern of DARPP-32 phosphorylation induced by D-amphetamine, LSD, and PCP would be predicted to result in synergistic inhibition of PP-1. In accordance with these biochemical observations, the effects of LSD and PCP, as well as of D-amphetamine, on sensorimotor gating and repetitive movements were reduced in DARPP-32 KO mice and in mice with point mutations at Thr 34 or Ser 130 of DARPP-32. 45 Caffeine: Caffeine, the most commonly used psychostimulant, acts as an antagonist at A 1 as well as A 2A adenosine receptors. 73 A role for A 1 adenosine receptors in the stimulatory actions of caffeine was initially suggested. However, it is now recognized that blockade of A 2A receptors is critical for the actions of caffeine. 73 , 74 Recent studies have provided strong evidence for an involvement of DARPP-32 in the stimulatory actions of caffeine. Systemic administration of caffeine, or of SCH58261, a selective A 2A receptor antagonist, causes an increase of Thr 75 -DARPP-32 in wildtype mice. 41 The stimulatory effects of caffeine and SCH 58,261 on locomotor activity, seen in wild-type mice, were greatly reduced in DARPP-32 KO mice. The blockade of a basally active A 2A /PKA/PP-2A/Thr 75 -DARPP-32 pathway may, therefore, play a critical role for the stimulatory actions of caffeine.
Ethanol: DARPP-32 appears to be involved in both acute and long-term responses to ethanol. Conditioned place preference studies of wild-type and DARPP-32 KO mice indicate a requirement for DARPP-32 in mediating ethanol reward. 75 DARPP-32 KO mice also exhibit a signifi cant decrement in ethanol self-administration. However, DARPP-32 KO mice show a greater sensitivity to the motor stimulant effect produced by a single injection of ethanol. Another recent study has shown that DARPP-32 appears to play a role in ethanol reinforcement by acting to regulate the ability of ethanol to inhibit NMDA receptor function. 76 In the presence of ethanol, NMDA synaptic currents are generally reduced. In brain regions containing DARPP-32, dopamine, via D 1 receptors, stimulates the PKA-mediated phosphorylation of the NR1 subunit of the NMDA receptor at Ser 897 . In DARPP-32 KO mice this regulation of NMDA receptors is absent, and activation of D 1 receptors does not prevent the ability of ethanol to inhibit NMDA receptors. Interestingly, moderate levels of ethanol increase phosphorylation of Thr 34 in striatal slices, although the mechanism involved has not been determined.
SUMMARY
A large body of work over the last two decades has found that DARPP-32, when phosphorylated at Thr 34 , acts as an amplifi er of PKA-mediated signaling through its ability to potently inhibit PP-1. This amplifying property of DARPP-32 is critical for dopaminergic signaling, but it is also utilized by multiple other neurotransmitters, including glutamate, serotonin and adenosine, in the striatum and other brain regions. In addition to its role as a PP-1 inhibitor, DARPP-32 when phosphorylated at Thr 75 inhibits PKA. Upon dopaminergic neurotransmission, the phosphorylation state at Thr 75 is reduced allowing disinhibition of PKA and further increasing phosphorylation at Thr 34 . This complex positive feedback loop potentiates dopaminergic sig naling.
An important component of our studies of DARPP-32 function, particularly those related to the actions of drugs of abuse, has been the use of DARPP-32 KO mice. More recently these studies have been complemented by generation of mice in which each of the 4 phosphorylation sites have been individually mutated. In future studies, these " phosphomutant " mice will be used to further dissect the precise roles played by Thr 34 , Thr 75 , Ser 97 (the mouse equivalent of Ser 102 ) and Ser 130 in the stimulatory and rewarding effects of drugs of abuse.
Other recent studies have indicated that the actions of dopamine and adenosine differ between sub-populations of striatal neurons. For example, a recent immunohistochemical study, 48 demonstrated that amphetamine and cocaine increase levels of Thr 34 -DARPP-32 phosphorylation mainly in striatonigral neurons. It will be important in the future to analyze DARPP-32 phosphorylation in either striatonigral or striatopallidal neurons in response to the actions of different drugs of abuse. We hope that these and other novel types of approach will enable us to identify protein kinases, protein phosphatases and phosphoprotein substrates that mediate the actions of drugs of abuse and that could be novel targets for development of treatments for drug dependence.
